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Background

Swine influenza A virus (IAV) reassortment with
2009 H1N1 pandemic (H1N1pdm09) virus has been documented,
and new genotypes and subclusters of H3N2 have since expanded in
the US swine population. An H3N2 variant (H3N2v) virus with the
H1N1pdm09 matrix gene and the remaining genes of swine triple
reassortant H3N2 caused outbreaks at agricultural fairs in 2011–
2012.

Results

To assess commercial swine IAV vaccines’ efficacy
against H3N2 viruses, including those similar to H3N2v, antisera
to three vaccines were tested by hemagglutinin inhibition (HI) assay
against contemporary H3N2. Vaccine 1, with high HI crossreactivity, was further investigated for efficacy against H3N2 virus
infection in pigs with or without maternally derived antibodies
(MDA). In addition, efficacy of a vaccine derived from whole
inactivated virus (WIV) was compared with live attenuated
influenza virus (LAIV) against H3N2.

Conclusions Swine IAV in the United States is complex and
dynamic. Vaccination to minimize virus shedding can help limit
transmission of virus among pigs and people. However, vaccines
must be updated. A critical review of the use of WIV in sows is
required in the context of the current IAV ecology and vaccine
application in pigs with MDA.

Methods

Hemagglutinin inhibition cross-reactivity demonstrated
that contemporary swine H3N2 viruses have drifted from viruses in
current swine IAV vaccines. The vaccine with the highest level of HI
cross-reactivity significantly protected pigs without MDA. However,
the presence of MDA at vaccination blocked vaccine efficacy. The
performance of WIV and LAIV was comparable in the absence of
MDA.

Keywords Antigenic drift, H3N2v, hemagglutinin inhibition, influenza A virus, maternally derived antibody, vaccines.

Please cite this paper as: Kitikoon et al. (2013) Swine influenza virus vaccine serologic cross-reactivity to contemporary US swine H3N2 and efficacy in pigs
infected with an H3N2 similar to 2011–2012 H3N2v. Influenza and Other Respiratory Viruses 7(Suppl. 4), 32–41.

Introduction
Transmission of influenza A virus (IAV) between people and
pigs results in a similar disease outcome. Three swine IAV
subtypes, H1N1, H3N2, and H1N2 are endemic in the
United States and world’s pig population.1 In the last two
decades, the emergence of H3N2 virus in 1998 and a number
of human-to-swine IAV spillover events in the United States
contributed to increased genetic diversity of swine IAV and
multiple co-circulating hemagglutinin (HA) gene subclusters.1 North American swine H3N2 viruses are characterized
by the triple-reassorted internal gene (TRIG) constellation of
human, swine, and avian lineages.2 The H3N2-TRIG viruses
were classified as H3 clusters I to III, a result of three
separate human seasonal H3 gene introductions in 1995
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(H3-I), 1997 (H3-II), and 1996 (H3-III), respectively,3 with
low serological cross-reactivity among the clusters.4–6 Swine
H3-IV evolved from cluster III and was reported in 2005,7
but remained relatively stable until 2010. From 1998 to 2009,
the majority, if not all endemic H1 and H3 swine IAV in the
United States contained the TRIG backbone.8 The TRIG was
also found in an increased number of swine-to-human cases
in the United States. Six human cases of classical swine
H1N1 viruses were reported between 1990 and 1995,
whereas the number increased to 21 from 1998-2010, and
all of these cases had the TRIG backbone (14 H1 and 7 H3
viruses).9 The introduction of the 2009 H1N1 pandemic
virus (H1N1pdm09) and reassortment with H3N2-TRIG
viruses (rH3N2p) altered both the genotype and phenotype
of the previously stable swine H3-IV viruses. At least 10

Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

Efficacy of swine influenza vaccines against H3N2

H3N2 genotype patterns emerged in the United States, with
subsequent HA evolution and emergence of H3-IV subclusters with inconsistent HI and serum neutralizing antibody
cross-reactivity among them.4,10 The H3N2 genotype that
inherited only the matrix gene from the H1N1pdm09 virus
in particular has raised public health concerns. This virus
caused over 340 H3N2v cases across 13 US states, with 16
cases hospitalized and 1 death.11 Infections mostly occurred
in children and were associated with direct exposure to pigs
at agricultural fairs. The H3 genes of the H3N2v in people
and closely related rH3N2p swine viruses fall into a
monophyletic cluster, IV-A.10 Along with the unique
genotype and HA cluster, the N2 gene is derived from a
human seasonal virus from 2002 instead of the N2-1998
lineage associated with the original swine H3N2-TRIG
virus.12 Data show that current trivalent human influenza
vaccine generates minimal HI cross-reactivity and would
likely provide no protection for this virus.13,14 Similar data
evaluating swine vaccines or population immunity in swine
herds against contemporary H3N2 have not been reported
previously. Additionally, data generated from the US
Department of Agriculture (USDA)-National Animal Health
Laboratory Network (NAHLN) voluntary swine IAV surveillance system during 2009–2012 (with over 1000 HA and
NA sequences) indicate that swine H3N2 isolates increased
in detection from under 25% in 2009–2010 to 33% in 2012
(T.K. Anderson, in press). This increase suggests that these
antigenically diverse rH3N2p may not be adequately
controlled by current approaches.
Control of IAV in pigs through vaccination is a common
practice in the USA. Current swine IAV vaccines are available
as licensed commercial products with whole inactivated virus
(WIV) preparations with oil-based adjuvants.15 The vaccine
strains vary in different regions of the world but usually
consist of two or more isolates of the H1 and H3 subtypes
(bivalent or multivalent vaccines). Vaccine efficacy of WIV
correlates well with the antigenic distance between the
vaccine strains and the circulating virus strains.16 As recent
swine IAV have become increasingly diverse, updating
vaccine strains in commercial vaccines has fallen behind,
and in response, autogenous vaccines have become common
among US swine producers. Vaccines are used primarily in
sow herds to induce maternally derived antibody (MDA) that
can pass to piglets through colostrum. Maternally derived
antibody from vaccinated sows can last up to 13–14 weeks.17
The presence of swine IAV-specific MDA may protect pigs
through the nursery period, but not the growing phase
where, although less common, vaccination is also used to
control IAV.18 A drawback associated with using WIV
vaccine is the presence of MDA at vaccination causes vaccine
failure.19 Additionally, using a mismatched vaccine/infection
strain of the same subtype or when heterologous MDA is
present at the time of vaccination with mismatched vaccine/

field strain can cause IAV vaccine-associated enhanced
respiratory disease (VAERD).20,21
Our study assessed cross-reactive hemagglutinin inhibition
(HI) antibody following vaccination with currently available
commercial swine IAV vaccines and contemporary US swine
H3N2 viruses (including swine rH3N2p viruses similar to the
human H3N2v viruses) against contemporary swine H3N2
viruses with genetically diverse H3 genes. A vaccine that
induced the highest HI cross-reactivity to tested viruses was
selected for further investigation to evaluate efficacy when
delivered in the presence or absence of heterologous MDA
(animal trial 1). Experimental WIV and live attenuated
influenza virus (LAIV) vaccines were also tested against
contemporary H3N2 challenge (animal trial 2). Vaccine
efficacy was based on the ability to decrease pneumonia,
virus replication in lungs, and shedding in pigs following
rH3N2p virus infection.

Materials and methods
Antisera production and hemagglutinin inhibition
cross-reactivity test
Twenty-three H3N2 viruses including one 1998 isolate, four
isolates from 2006 to 2010, and 18 isolates from 2011 to 2012
(including a human H3N2v and three nearly identical swine
viruses associated with 2011–2012 county fair cases) were
selected as HI test antigens and/or antigens for swine IAVantisera production. The hemagglutinin genes of all viruses
in this study were characterized according to established
criteria as either H3 cluster I or IV-A to F.10 An H3
phylogeny demonstrating cluster and subcluster relationships
is presented in Figure S1. In addition, three US commercial
swine IAV vaccines were used for the generation of antisera
to determine their cross-reactivity against the selected swine
isolates. Viruses and vaccines included are listed in Table 1.
Three-week-old cross-bred pigs were obtained from a herd
free of IAV, porcine reproductive and respiratory syndrome
virus (PRRSV), and Mycoplasma hyopneumoniae (MHYO).
For each virus, two pigs were immunized with 256 hemagglutinin units (HAU) of ultraviolet (UV)-inactivated IAV
combined with 20% commercial adjuvant (Emulsigen D;
MVP Technologies, Omaha, NE, USA) by intramuscular
(IM) route. Two or three doses of inactivated vaccines were
given approximately 2–3 weeks apart. Commercial swine
IAV vaccines were administered according to the manufacturers’ guidance with the exception of vaccine 3 where an
additional dose was administered. When HI titers to
homologous virus reached at least 1:160, pigs were humanely
euthanized with pentobarbital sodium (Fatal Plus; Vortech
Pharmaceuticals, Dearborn, MI, USA) for blood collection.
Sera were collected and stored at 80°C.
Prior to HI testing, sera were treated with receptordestroying enzyme (Sigma-Aldrich, St. Louis, MO, USA),
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Table 1. Swine H3N2 viruses and commercial swine influenza A virus
(IAV)-inactivated vaccines used for the generation of antisera* and
test antigen in the hemagglutination inhibition assay

Viruses and vaccines

HA
cluster

HA
accession#

Viruses
A/swine/Texas/4199-2/1998
A/swine/Minnesota/01146/2006
A/swine/Minnesota/02782/2009*
A/swine/Illinois/02907/2009

H3-I
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV (A)
H3-IV (A)

CY095675
CY099035
CY099103
KF73938
7
JF263535
JN638733
JN940422

H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV
H3-IV

JX534982
JX422497
JX657030
JX422257
JX422521
JX657018
JX092535
CY107066
JX092307
JX092542
JQ739697
JN652493
JN652507
JX422557
JX092555
JX422575

A/swine/Pennsylvania/A01076777/2010
A/Indiana/08/2011**
A/swine/New
York/A01104005/2011*, ***
A/swine/Indiana/A00968373/2012*, ***
A/swine/Illinois/A01241469/2012
A/swine/Minnesota/A01300213/2012
A/swine/Minnesota/A01125993/2012
A/swine/Minnesota/A01327922/2012
A/swine/Iowa/A01300195/2012
A/swine/Indiana/A01202866/2011
A/swine/Illinois/A01201606/2011
A/swine/Iowa/A01202613/2011
A/swine/Iowa/A01202889/2011
A/swine/Iowa/A01203196/2012
A/swine/Iowa/A01049750/2011
A/swine/Texas/A01049914/2011
A/swine/Illinois/A01241066/2012
A/swine/Iowa/A01203121/2012
A/swine/Nebraska/A01241171/2012
Vaccines*
Vaccine 1 (FluSureâ XP, Zoetis
Animal Health)
A/swine/North Carolina/031/2005
A/swine/Iowa/110600/2000
A/swine/Oklahoma/0726H/2008
A/swine/Missouri/069/2005
Vaccine 2 (MaxiVacExcellâ 5.0, Merck
Animal Health)

Vaccine 3 (PneumoStar, Novartis)

(A)
(A)
(B)
(B)
(B)
(B)
(C)
(D)
(D)
(D)
(D)
(F)
(F)
(F)
(F)
(F)

H1-Delta
1
H1Gamma
H1-Delta
2
H3-IV
H1-Beta
H1Gamma
H1-Delta
H3-I
H3-IV
H1-Alpha
H3-I

HA, hemagglutinin.
**H3N2 variant (H3N2v) virus from human case.
***H3N2 viruses genetically similar to H3N2v.

heat inactivated at 56°C for 30 minutes, and adsorbed with
50% turkey red blood cells (RBCs). Hemagglutinin inhibition assays were performed with four HAU of virus antigen
and 05% turkey RBC according to standard techniques.22
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Geometric mean titers were used to calculate the fold change
between heterologous and homologous reactions. Fold
changes were then used to generate a heat map indicating
level of cross-reactivity. The percentage of cross-reactivity for
each antiserum was calculated by dividing the number of
virus antigens that cross-reacted with antisera (<4-fold
reduction) by the total number of viruses tested. The
commercial vaccine that provided the highest HI crossreactivity was used in subsequent experiments.

In vivo experimental design
Two separate animal trials were conducted to (i) investigate
the role IAV-specific MDA have on commercial vaccine
immunogenicity and efficacy; and (ii) compare vaccine
efficacy between WIV and LAIV against an rH3N2p virus
genetically similar to the human H3N2v viruses reported in
2011–2012. Ten 3-week-old conventional pigs with swine
IAV-specific MDA were obtained from previously na€ıve sows
that were vaccinated with an experimental WIV at 128 HAU
[A/swine/Texas/4199-2/1998 (TX98, H3N2 cluster I, MDA
strain)] derived as described in Antisera production and
hemagglutinin inhibition cross-reactivity test and 33, and
3-week-old conventional pigs without MDA were procured
from a high-health status herd free of IAV, PRRSV, and
MHYO. Upon arrival, pigs without IAV-specific MDA were
confirmed seronegative by Flock Check AI MultiS-Screen
diagnostic kit (IDEXX Laboratories, Westbrook ME, USA).23
To reduce bacterial contaminants, all pigs were treated with
ceftiofur crystalline-free acid (Excede; Zoetis Animal Health,
Florham Park, NJ, USA) and enrofloxacin (Baytril 100; Bayer
HealthCare AG, Monheim, Germany). The experimental
protocol is summarized in Table 2. The eight pig groups
were housed in individual isolation rooms and cared for in
compliance with the Institutional Animal Care and Use
Committee of the National Animal Disease Center.
FluSureâ XP (Vaccine 1; Zoetis Animal Health) was used
in trial 1 to study the effect of IAV-specific MDA on
commercial vaccine efficacy. Pigs in groups MDA/V/C and
V/C were vaccinated at 4 weeks of age and boosted 3 weeks
later according to manufacturers’ recommendation. In trial
2, two vaccine platforms were used, WIV and LAIV, with
the vaccine strain of both from a cluster IV swine triple
reassortant H3N2 A/turkey/Ohio/313053/2004 (OH04).
Whole inactivated virus was prepared as described in
Antisera production and hemagglutinin inhibition crossreactivity test and administered IM to the WIV/C group at
approximately 4 weeks of age and boosted at 7 weeks of
age. The LAIV H3N2 OH04,24 contains modifications to the
viral polymerase genes to decrease virus polymerase activity
and impair virus growth in normal core body temperatures.25 Pigs in the LAIV/C group were vaccinated and
boosted with 1 ml of 106 50% tissue culture infective dose
(TCID50) per ml virus intranasally (IN) at the same timing
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Table 2. Animal study design

Group

MDA to TX98

Trial 1
MDA/C
Yes
MDA/V/C
Yes
V/C
No
C
No
Trial 2
WIV/C
No
LAIV/C
No
C
No
Negative control
NEG
No

Vaccine
status

Challenge
with NY11

n

No
Yes (vaccine 1)
Yes (vaccine 1)
No

Yes
Yes
Yes
Yes

5
5
5
5

Yes (OH04)
Yes (OH04)
No

Yes
Yes
Yes

6
6
6

No

No

5

calculated based on weighted proportions of each lobe to the
total lung volume.26
Tissue samples from the distal trachea and right cardiac
lung lobe and/or affected lobes were fixed in 10% buffered
formalin for histopathologic examination. A single pathologist blinded to the treatment groups scored all tissues.27
Bronchoalveolar lavage fluid (BALF) was collected at
necropsy by lavaging lungs with 50 ml minimal essential
medium (MEM) were screened for additional respiratory
pathogens including PRRSV, porcine circovirus type 2
(PCV2), and MHYO nucleic acid by real-time RT-PCR test
with VetMax NA and EU PRRSV, VetMax PCV2 (custom
assay), and VetMax MHYO kits, respectively (Life Technologies, Carlsbad, CA, USA).

Virus titer in lungs and nasal swabs
C, challenged; MDA, maternal derived antibody; V, vaccinated; NEG,
non-vaccinated, non-challenged (negative control); WIV, whole virus
inactivated vaccine; LAIV, live attenuated influenza vaccine; TX98, A/
swine/Texas/4199-2/1998 (H3N2); NY11, A/swine/New York/
A01104005/2011 (H3N2).

as the WIV group. In trials 1 and 2, five and six pigs,
respectively, served as non-vaccinated, challenged positive
control groups (C). In addition, one group of five pigs
served as non-vaccinated, non-challenged negative controls
(NEG).
Pigs in both trials were challenged intratracheally (2 ml)
and IN (1 ml) with 1055 TCID50 per ml of virus A/swine/
New York/A01104005/2011 (NY11), a swine rH3N2p similar to H3N2v, approximately 2 weeks following booster
(0 days post-infection, dpi). Viral inocula were backtitrated in Madin–Darby canine kidney (MDCK) cells.
Inoculation was performed under anesthesia administered
IM, using an anesthetic cocktail of ketamine (8 mg/kg),
xylazine (4 mg/kg), and Telazol (6 mg/kg, Zoetis Animal
Health, USA). Pigs were observed daily for clinical signs of
respiratory disease. Rectal temperatures were taken at
1 dpi and daily until 5 dpi. All pigs were humanely
euthanized with a lethal dose of pentobarbital and necropsied at 5 dpi.
Genetic similarity of the HA between MDA vaccine strain,
antisera vaccine strains, and challenge strain was calculated
in MEGA v5.05 (Table S1). The MDA strain (TX98) had
913% amino acid identity with the challenge strain (NY11),
and the LAIV strain (OH04) had 97% identity with the
challenge strain.

Macroscopic and microscopic examination of lungs
At necropsy, lungs were removed and evaluated for the
percentage of the surface affected with pneumonia for each
lung lobe, and a total percentage for the entire lung was

To evaluate virus shedding, nasal swabs (NS) were collected
on 1, and 1, 3, and 5 dpi from both trials and placed in
2 ml MEM. To assess IAV titers in lungs, BALF was collected
from all pigs at necropsy. All NS and BALF were stored at
80°C until study completion.
For virus titration, NS and BALF samples were serially
diluted (10-fold) with serum-free Opti-MEMâ reduced serum
medium (Life Technologies) supplemented with TPCK trypsin
and antibiotics. Each dilution was plated in triplicate (100 ll
per well) onto PBS-washed confluent MDCK cells in 96-well
tissue culture plates. At 48 hour, plates were fixed with 4%
phosphate-buffered formalin and stained using immunocytochemistry with an anti-influenza A nucleoprotein monoclonal
antibody.20 Virus titer was calculated for each sample using the
Reed and Muench method.28

Hemagglutination inhibition assay
The HI assays were performed as described in Antisera
production and hemagglutinin inhibition cross-reactivity test
to measure MDA titers and detect systemic antibody
response to vaccination and infection. Serum samples were
collected prior to vaccinations and challenge ( 35, 14, and
0 dpi), and at necropsy (5 dpi). H3N2 virus antigens utilized
in the HI assay included the challenge virus (NY11), MDA
strain (TX98), a putative commercial vaccine 1 strain (A/
Swine/Missouri/069/2005; vaccine 1), and laboratory WIV
and LAIV strain (OH04).

ELISA for mucosal influenza A virus-specific
antibody detection
Prior to testing, BALF was incubated at 37°C for 1 hour with
an equal amount of 10 mM dithiothreitol (DTT; SigmaAldrich) to disrupt mucus. ELISAs for mucosal IAV
antibodies to challenge virus (NY11) were performed on
each BALF sample in duplicate.21 Antibody levels were
reported as the mean optical density (OD), and the mean OD
of each treatment group was compared.
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Table 3. Heat map indicating hemagglutinin inhibition (HI) titer reduction between homologous and heterologous titers. Percentage of crossreactivity for each antisera was calculated by dividing the number of virus antigens with high cross-reactivity (<4-fold) by the total number of viruses
tested

Sera (cluster)

I

IV

IV

I & IV

I

Virus(cluster)

TX/1998

MN/2009

IL/2009

PA/2010

IN/2011

NY/2011

IN/2012

Vaccine 1

Vaccine 2

Vaccine 3

A/Sw/TX/4199-1/1998
(I)
A/Sw/MN/01146/2006
(IV)
A/Sw/MN/02782/2009
(IV)
A/Sw/IL/02907/2009
(IV)
A/Sw/PA/A01076777/2010
(IV)
A/IN/08/2011
(IV-A)
A/Sw/NY/A01104005/2011 (IV-A)
A/Sw/IN/A00968373/2012
(IV-A)
A/Sw/IL/A01241469/2012
(IV-A)
A/Sw/MN/A01300213/2012 (IV-B)
A/Sw/MN/A01125993/2012 (IV-B)
A/Sw/MN/A01327922/2012 (IV-B)
A/Sw/IA/A01300195/2012
(IV-B)
(IV-C)
A/Sw/IN/A01202866/2011
A/Sw/IL/A01201606/2011
(IV-D)
A/Sw/IA/A01202613/2011
(IV-D)
A/Sw/IA/A01202889/2011
(IV-D)
A/Sw/IA/A01203196/2012
(IV-D)
A/Sw/IA/A01049750/2011
(IV-F)
A/Sw/TX/A01049914/2011
(IV-F)
A/Sw/IL/A01241066/2012
(IV-F)
A/Sw/IA/A01203121/2012
(IV-F)
A/Sw/NE/A01241171/2012 (IV-F)
% cross-reacƟvity

17·4

95·6

21·7

39·1

52·2

82·6

73·9

69·6

65·2

34·8

homologous virus

< 4 fold reducƟon

Statistical analysis
The percent macroscopic pneumonia, microscopic lesion
scores, log10 transformations of BALF and NS virus titers,
and log2-transformed HI titers were analyzed using analysis
of variance (ANOVA). Significant differences between treatment groups were evaluated using the Tukey–Kramer HSD
multiple comparison test, with a P-value of ≤005 considered
significant. All data analyses were performed using GraphPad
Prism 5.03 (GraphPad Software, Inc., La Jolla, CA, USA).

Results
Hemagglutination inhibition cross-reactivity
Pairwise HI cross-reactivity is presented as a heat map, indicating
the fold reduction obtained by dividing the log2-transformed
reciprocal titer to heterologous antigen by the homologous
antigen titer (Table 3). Sera from pigs vaccinated with the H3-I
(TX98) had limited cross-reactivity (174%) with contemporary
H3-IV isolates. The percentages of HI cross-reactivity detected
between antisera produced against the two 2009 viruses, MN/
2009 (956%) and IL/2009 (217%), were highly variable. Overall
percentages of cross-reactivity of antisera against 2010–2012
viruses ranged from 391% to 826%. Serum from pigs exposed
to H3 cluster IV(A) viruses, including H3N2v (IN/2011) and

36

A

4 to 8 fold reducƟon

> 8 fold reducƟon

swine IV(A) rH3N2p (NY/2011 and IN/2012), had a range in
reactivity to recent H3-IV viruses (522–826%). Vaccine 1,
containing a 2005 H3-IV strain, showed limited cross-reactivity
to H3-I virus, but an overall 696% had cross-reactivity to H3-IV
viruses. Vaccine 2, containing H3-I and -IV strains, cross-reacted
with H3-I virus but had 652% cross-reactivity to H3-IV viruses.
Vaccine 3 containing an H3-I virus cross-reacted with the tested
H3-I virus but had low cross-reactivity (348%) to H3-IV viruses.
Antisera to vaccines 1 and 2 cross-reacted well with H3N2v and
all three IV-A rH3N2p swine isolates, while vaccine 3 had
minimal cross-reactivity to the H3N2v isolate but cross-reacted
to the swine IV-A rH3N2p. In general, all three vaccines
appeared to be more cross-reactive with H3 IV-A and IV-F
viruses but had reduced cross-reactivity to H3 IV-B and IV-D
viruses. Vaccine 1 had the highest level of HI cross-reactivity
among the three vaccines and was selected for further analysis of
vaccine efficacy.

Clinical signs, macroscopic and microscopic
findings
Clinical signs
None of the non-infected control pigs or the infected animals
in either trial displayed IAV-associated respiratory signs.
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Maternally derived antibody alone reduced fever, as only the
positive control pigs (Group C) in trial 1 spiked a fever
≥104°F at 1 and 2 dpi (Figure S2). Rectal temperatures of all
animals in trial 2 remained below the febrile cutoff during
the trial period (data not shown).

Macroscopic and microscopic lesions
Back titration from challenge inocula indicated that pigs in
trial 1 were infected with 1055 TCID50/ml, while pigs in trial
2 received 104 TCID50/ml virus. Mean macroscopic lesions
were not statistically different between challenge groups in
either trial. One pig vaccinated in the presence of MDA had
enhanced macroscopic lesions of 186% (Figure 1A), while
the remaining pigs in the same group had <6% lung lesions.
Statistical differences were detected in the IAV-associated
microscopic pneumonia scores (Figure 1A, B). In trial 1, V/C

pigs had significantly reduced scores compared with C pigs
and MDA/V/C pigs. Maternally derived antibody alone did
not reduce microscopic lesions as the scores were similar to
groups C and MDA/V/C. In trial 2, pigs vaccinated with both
experimental vaccine platforms had significantly lower
pneumonia scores compared with non-vaccinated, challenged pigs.

Virus in lungs and nasal swabs
All vaccinated pigs had a significantly reduced amount of
virus in the lungs on 5 dpi compared with non-vaccinated,
challenged positive control groups (Figure 2A, B). Maternally derived antibody alone did not reduce virus replication
in lungs. In trial 2, both WIV and LAIV significantly reduced
virus in the lungs, and the level of virus was not different
between the vaccinated groups.

Figure 1. Percentage of macroscopic lesion
from MDA/C, MDA/V/C, and V/C pigs from
trial 1 (A) and C, WIV/C, and LAIV/C pigs in trial
2 (B) at 5 days post-infection. Average
microscopic lesion scores  SEM of each
treatment group are indicated in table. Means
with different letters within a column are
statistically different (P ≤ 005). Nonchallenged pigs had no macroscopic and
microscopic lesion scores and are not included.
C, challenged; MDA, maternal derived
antibody; V, vaccinated; WIV, whole virus
inactivated vaccine; and LAIV, live attenuated
influenza vaccine.

Figure 2. Average virus titers in lungs (A, B) at
5 days post-infection (dpi) and nasal swabs (C,
D) at 1, 3, and 5 dpi from C, MDA/C, MDA/V/
C, and V/C pigs from trial 1 (A and C) and from
C, WIV/C, and LAIV/C in trial 2 (B and D) as
mean log10 TCID50/ml  SEM. Different
superscript letters or * within the figure are
significant difference between the values
(P ≤ 005). Virus was not isolated from any
non-challenged pigs, and results are not
included. C, challenged; MDA, maternal
derived antibody; V, vaccinated; WIV, whole
virus inactivated vaccine; and LAIV, live
attenuated influenza vaccine.
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Pigs in the V/C group shed significantly reduced levels of
virus in nasal secretions compared with positive controls in
trial 1 on 1, 3, and 5 dpi (Figure 2C). Maternally derived
antibody alone or MDA with vaccination did not reduce
nasal shedding. In trial 2, no virus was detected in LAIV/C
pigs, while one pig in WIV/C group shed virus at 1 dpi
(Figure 2D). No virus was isolated from negative control
pigs at any time point (data not shown).

Serum hemagglutinin inhibition antibody
In trial 1, MDA pigs had average reciprocal HI titers of 160
to MDA strain (TX98) prior to the first vaccination, and
the level decreased approximately 2-fold by the end of the
study (Figure 3A). Pre-vaccination MDA appeared to have
moderate cross-reactivity to the challenge strain (NY11)
and less cross-reactivity to the commercial vaccine strain
(Figure 3B, C). Piglets derived from non-vaccinated sows
did not have HI titers to any tested virus prior to
vaccination, and all negative control pigs remained seronegative throughout the study (data not shown). V/C pigs

had HI titers to vaccine 1 (1:640) after two vaccinations and
high cross-reactivity to the challenge strain. Maternally
derived antibody significantly reduced vaccine immunogenicity as reflected by lower HI titers to both vaccine 1 and
challenge viruses in MDA/V/C pigs compared with V/C
pigs. In trial 2 (Figure 3D, E) after the booster dose, WIV/C
pigs had significantly higher HI titers to both vaccine strain
(OH04) and challenge virus compared with LAIV/C vaccinated pigs, yet both vaccines were highly efficacious in nonMDA vaccinated pigs.

Mucosal SIV-specific antibody
At 5 dpi, there was detectable IgG specific to challenge virus
(NY11) in the lungs of vaccinated pigs regardless of MDA
and vaccine platform (WIV or LAIV). Post-challenge V/C
pigs had significantly higher levels of NY11-specific IgA in
the lungs only if the vaccine was administered in the absence
of MDA (Figure 4A). The LAIV/C pigs had significantly
higher levels of NY11-specific IgA in the lungs compared
with all other groups (Figure 4B).

Figure 3. Average hemagglutinin inhibition
(HI) titers against maternal derived antibody
strain, TX98 (A), commercial vaccine 1 strain
(B), experimental vaccine strain, OH04 (D), and
challenge virus strain, NY11 (C and E). Sera
were collected prior to first and second
vaccination ( 35 and 14 days post-infection;
dpi), prior to influenza A virus (IAV) infection
(0 dpi) and at 5 dpi. Sera were collected from
C, MDA/C, MDA/V/C and V/C pigs from trial 1
(A–C) and from C, WIV/C, and LAIV/C pigs in
trial 2 (D, E). Means with different letters at the
same time point are statistically different
(P ≤ 005). Non-challenged pigs had no HI
titers, and results are not included. C,
challenged; MDA, maternal derived antibody;
V, vaccinated; WIV, whole virus inactivated
vaccine; and LAIV, live attenuated influenza
vaccine.
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Figure 4. Average O.D.  SEM of NY11 (challenge virus) -specific IgG and -specific IgA from lower airways of NEG, C, MDA/C, MDA/V/C, and V/C pigs
in trial 1 (A) and from NEG, C, WIV/C, and LAIV/C pigs in trial 2 (B) measured by ELISA on 5 dpi. Means with different letters or * within a column are
statistically different (P ≤ 005). NEG, non-vaccinated, non-challenged; C, challenged; MDA, maternal derived antibody; V, vaccinated; WIV, whole virus
inactivated vaccine; and LAIV, live attenuated influenza vaccine.

Discussion
Here, we demonstrated that contemporary swine H3N2
viruses selected from subclusters of H3-IV have drifted
antigenically, affecting the efficacy of currently available
commercial swine-inactivated vaccines in the United States.
These genetically distinct clusters of viruses continue to
diversify and represent a challenge for IAV control. One
commercial vaccine had limited cross-reactivity to over half
the contemporary viruses tested, although it was not unexpected as the vaccine strain was H3-I, while the majority of
the viruses tested were H3-IV. The other two vaccines
containing H3-IV vaccine strains appeared to cross-react with
the H3N2v and similar rH3N2p viruses, but elicited moderate
to significantly reduced cross-reactivity to many of the ten
representative 2012 viruses tested. Data from human influenza vaccines indicate that vaccine updates are required when
a >8-fold reduction HI antibody (>4-fold of log2-transformed
HI antibody) is detected.29 Results of HI cross-reactivity using
antisera generated with three commercial vaccines suggest a
reduction in vaccine efficacy against contemporary swine
H3N2 strains.
To date, all commercially available swine IAV vaccines are
inactivated bivalent or multivalent formulations including
H1 and H3 subtype strains or a combination of strains
representing the distinct subclusters.15 The HA is the primary
immune target responsible for WIV-mediated protection
against IAV infection. Limited cross-reactive antibodies to
different HA subtypes, or clusters within the same subtype, is
one of the major obstacles for optimal WIV vaccine efficacy.
The presence of IAV-specific MDA in weanling pigs at the
time of vaccination is another factor that further limits WIV
vaccine performance. Piglets born to sows that have been
repeatedly vaccinated can have serum antibodies to H1N1
and H3N2 viruses until 13–14 and 9–10 weeks of age,
respectively.17 While IAV-specific MDA can reduce clinical
disease in piglets, MDA-positive piglets infected with IAV
shed virus longer than pigs without MDA,30 and a negative
correlation was observed between swine IAV-specific MDA

levels at vaccination and the development of primary
antibody response to the vaccine.17 Consistent with previous
studies, we report that the efficacy of a commercial
inactivated swine IAV vaccine administered to pigs in the
presence of MDA was markedly reduced. Maternally derived
antibody-negative pigs given two doses of vaccine had
antibodies cross-reactive to the challenge virus and had
significantly reduced levels of rH3N2p virus in lungs and
nasal cavities following challenge. The presence of MDA at
vaccination interfered with the development of humoral
immunity and subsequently reduced vaccine efficacy. This
occurred despite the low HI cross-reactivity level between
MDA and the vaccine strain (<1:40) at vaccination. Reduced
pneumonia is used as a parameter to assess IAV vaccine
protection in pigs, but pneumonia was not different between
any groups tested here. H3N2v was shown to cause fewer
lung lesions when compared with endemic swine H3N2TRIG viruses,31 and consequently may not be a valid
measurement, particularly with viruses that do not induce
high percentages of pneumonia. One caveat is that our study
had a limited number of animals, which may have reduced
the power to detect small differences in lung lesion scores.
However, there was one striking result, one pig vaccinated in
the presence of MDA had a percentage of macroscopic lung
lesions three times over the group mean detected in nonvaccinated positive control pigs. Previous data using an
inactivated adjuvanted IAV vaccine reported the occurrence
of VAERD in vaccinated, MDA-positive pigs where the MDA
vaccinated and challenge viruses were heterologous strains of
the same subtype.20,21 These findings reflect events in the
field where mis-matching of MDA, vaccine, and circulating
strains is expected to be common.
Recent studies with vectored and LAIV vaccines have
suggested that they improve immunity to heterologous IAV
strains,32 with a reduction in MDA interference33,34 and
avoidance of MDA-VAERD.21 This study compared the
capability of experimental LAIV and WIV platform vaccines
(with the identical vaccine strain, OH04). The difference in
lung lesions between the infected groups was not definitive

Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

39

Kitikoon et al.

because pneumonia was relatively mild. Both vaccine platforms were comparable in limiting virus replication in lungs,
demonstrating the performance of WIV is effective in the
absence of MDA. However, the LAIV completely prevented
nasal shedding. Mucosal immunity likely played a major role
as the LAIV-vaccinated pigs had significantly higher mucosal
IgA than WIV pigs but barely detectable challenge virusspecific HI antibodies in serum. It is known that secretory
IAV-specific IgA is important in defending both the upper
and lower respiratory tract, while serum IAV-specific IgG
protects the lower respiratory tract.16 Although not measured
here, cell-mediated immunity (CMI) must have a role in
protection: a previous study using similar LAIV modified by
replacing the H3 and N2 of the attenuated OH04 virus with
H1 and N1 from a H1N1pdm09 strain demonstrated higher
CMI response with increased IFN-gamma secreting cells and
T cell populations.35 Following infection, the LAIV vaccine in
that study induced sterilizing immunity, while pigs vaccinated with WIV had virus in lungs and nasal cavities.25
Influenza continues to be a major health problem for
swine, and new reassortant strains periodically cause public
health threats. Vaccination remains an essential tool in
controlling IAV in pigs. However, the increasing antigenic
diversity of IAV makes development of adequate WIV
vaccines for swine challenging. This study indicates that
contemporary swine H3N2 viruses have drifted from the
currently available swine vaccines. The rH3N2p virus similar
to H3N2v used in this study caused mild clinical disease, but
replicated and shed well from the nasal cavities. This is an
advantage to the virus in spreading among immunologically
naive pigs and people. Commercial WIV in non-MDA pigs
reduced virus in lungs and nasal cavities, but the response
was diminished when vaccinated in the presence of heterologous MDA. Although not tested in pigs with MDA here,
LAIV was previously shown to be more effective than WIV,21
and LAIV should be considered as an improved vaccine
platform over WIV under appropriate conditions. Our
vaccine study underscores the need for improving the
process of swine IAV vaccine strain updates as well as
consideration of a variety of appropriate vaccine platforms.
Similarly, the extensive use of WIV in sows to increase MDA
that is mismatched to the circulating strains to which piglets
are exposed should be re-evaluated.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Percent nucleotide identity of the hemagglutinin
(HA) gene compared between H3N2 isolates used in the
animal trials.
Figure S1. Phylogeny of representative and study H3N2
influenza A isolates using the hemagglutinin (HA) gene.
Figure S2. Average rectal temperature of nonvaccinated,
challenged pigs (C), MDA+ -nonvaccinated, challenged pigs
(MDA/C), MDA+ -vaccinated, challenged pigs (MDA/V/C),
and MDA -vaccinated, challenged pigs (V/C) before
infection (0 days post infection; dpi) and after infection
(1–5 dpi) with NY11 (H3N2v-like virus) at 7 weeks of age.
Results of nonchallenged pigs are not included.

Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

41

Supplemental data
Table S1. Percent nucleotide identity of the hemagglutinin (HA) gene compared between H3N2 isolates used in the animal trials

Virus

Purpose in study

Percent Identity

Short
Name

TX98

OH04

MN06

A/swine/TX/4199-2/1998

MDA strain in trial 1

TX98

100

A/turkey/OH/313053/2004

WIV and LAIV strain in trial 2

OH04

93.3

100

A/swine/MN/01146/2006

Vaccine 1 surrogate

MN06

92.2

98.8

100

A/swine/NY/A01104005/2011

Challenge strain in trials 1 & 2

NY11

91.3

97.2

96.7

NY11

100

Note: The virus in commercial vaccine 1 is proprietary, thus percent identity between the virus vaccine and other viruses in the animal trial could not
be performed. The putative strain MN06 is included as a surrogate.

Figure S1. Phylogeny of representative and study H3N2 influenza A isolates using the hemagglutinin (HA) gene. Tree was constructed using the
neighbor-joining method in MEGA 5.2.1: numbers above or below branches indicate bootstrap support (%) estimated from 500 resamplings of the

sequence data (bootstrap values ≤ 50% are not show). H3 Cluster-IV subclusters A to F and Cluster-I are identified by bolded square parentheses.
Taxon names indicate viral isolate, preceded by Genbank or GISAID EpiFlu accession identifiers. Isolates marked by solid squares were included in
the HI cross-reactivity assay; H3N2v isolates and those used in the animal trials are labeled in parentheses following the taxon name. Scale bar
indicates nucleotide substitutions per site.
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Figure S2. Average rectal temperature of nonvaccinated, challenged pigs (C), MDA+ -nonvaccinated, challenged pigs (MDA/C), MDA+ vaccinated, challenged pigs (MDA/V/C), and MDA- -vaccinated, challenged pigs (V/C) before infection (0 days post infection; dpi) and after
infection (1-5 dpi) with NY11 (H3N2v-like virus) at 7 weeks of age. Results of nonchallenged pigs are not included. Temperature over > 104oF
indicates fever.

